Jean Park, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1861512592
Payments from drug & device makers
Across 1,720 payments — averaging $2128.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2.5M
- Novo Nordisk AS$297K
- Sanofi US Services Inc.$174K
- Boehringer Ingelheim Pharma GmbH & Co.kg$128K
- Boehringer Ingelheim International GmbH$102K
- Janssen Research & Development, LLC$73K
- plus $344K from 11 others
Across 20 payments — averaging $2663.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$51K
- Corcept Therapeutics$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 75 | $2,544,422 |
| Novo Nordisk AS | 1,470 | $297,238 |
| Sanofi US Services Inc. | 23 | $173,621 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 10 | $128,089 |
| Boehringer Ingelheim International GmbH | 25 | $101,645 |
| Janssen Research & Development, LLC | 12 | $73,008 |
| Novartis | 4 | $68,388 |
| Medtronic(2 entities) | 20 | $67,811 |
| Kowa Research Institute, Inc. | 29 | $57,103 |
| Dexcom, Inc. | 14 | $53,143 |
| Sanofi-aventis U.S. LLC | 5 | $35,390 |
| Amgen | 6 | $35,038 |
| Bayer | 12 | $26,333 |
| Novo Nordisk | 4 | $204 |
| Corcept Therapeutics | 7 | $173 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $28 |
How this compares
$3,661,668 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Baltimore
- Ilias SpanakisBaltimore$2.6M
- Philip LevinBaltimore$702K
- Roberto SalvatoriBaltimore$403K
- Thomas DonnerBaltimore$197K
- Adrian DobsBaltimore$190K
- Todd BrownBaltimore$143K
- Nowreen HaqBaltimore$85K
- Nanette SteinleBaltimore$74K
- Paul SackBaltimore$69K
- Asif MohamedBaltimore$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.